ClinicalTrials.gg
No longer availableNCT06004128Updated Jun 3, 2024

Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments

An expanded access record providing VYD222 in COVID-19, sponsored by Invivyd, Inc.. No longer available. Per ClinicalTrials.gov, last updated 2024-06-03.

Sponsored by Invivyd, Inc. · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Individual patients
Sex
All
01

Study summary

Provide pre-approval single-patient Expanded Access (Compassionate Use) of VYD222 for patients with symptomatic COVID-19 refractory to other treatments.

02

Conditions studied

  • COVID-19

Browse trials for

03

In context

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Lead sponsor

Invivyd, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
This record does not list eligibility criteria. Contact the study team before assuming you do or do not qualify.
05

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

  • DrugVYD222

    Monoclonal antibody

06

Where to request access

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT06004128
Lead sponsor
Invivyd, Inc.
Responsible party
Sponsor
First posted
Aug 22, 2023
Last update
Jun 3, 2024
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion